Signal from the log
Tenpoint Therapeutics
85 M$ en fonds propres · Series B · United Kingdom · Biotech
Biotech britannique et américaine d'ophtalmologie qui commercialise YUVEZZI, un collyre en dose unique approuvé par la FDA contre la presbytie, et développe des programmes sur la cataracte et l'atrophie géographique. Le tour annoncé de 235 M$ se décompose en 85 M$ de fonds propres en série B et 150 M$ de dette : seule la première part est un tour de table.
Verified
Announced on , logged by the watch of 17 August 2026.
- Operation
- Funding round
- Announced amount
- 85 M$ en fonds propres
- Stage
- Series B
- Country
- United Kingdom
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Janus Henderson , EQT Nexus , Hillhouse , British Business Bank , with Hercules Capital
Provenance
Source longevity
Logged on 17 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.